Telisotuzumab adizutecan
- Generic Name
- Telisotuzumab adizutecan
AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC
• AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.
• The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients.
• A phase 3 trial (TeliMET-NSCLC-01) is underway, comparing Teliso-V to docetaxel in c-Met-positive, non-squamous NSCLC patients.
• Teliso-V targets c-Met, a protein involved in cancer progression and resistance to therapies like EGFR inhibitors, offering a novel approach.
Telisotuzumab Adizutecan Shows Promise in c-Met-Expressing Solid Tumors
• Telisotuzumab adizutecan (ABBV-400) demonstrates antitumor activity in non-small cell lung cancer (NSCLC) and gastroesophageal cancer (GEA) patients in a Phase 1 study.
• In EGFR wild-type NSCLC, ABBV-400 achieved a 43.8% objective response rate (ORR) and an 85.4% clinical benefit rate at 2.4/3.0 mg/kg every three weeks.
• GEA patients treated with ABBV-400 at 3.0 mg/kg every three weeks showed a 28.6% ORR and a 71.4% clinical benefit rate.
• Promising initial results were observed in heavily pretreated metastatic colorectal cancer (CRC) patients with high c-Met expression, with an ORR of 37.5%.
ESMO 2024: AbbVie and Nuvalent Present Promising Data on Novel Cancer Therapies
• AbbVie presented data on mirvetuximab soravtansine for platinum-sensitive ovarian cancer, showing a 51.9% objective response rate in pre-treated patients.
• Nuvalent's NVL-655 and zidesamtinib demonstrated durable responses in heavily pre-treated NSCLC patients, targeting ALK and ROS1, respectively.
• AbbVie's telisotuzumab vedotin (Teliso-V) is under FDA review for accelerated approval in c-Met overexpressing non-small cell lung cancer.
• Nuvalent plans to initiate a Phase 3 trial (ALKAZAR) of NVL-655 in TKI-naïve ALK-positive NSCLC patients in the first half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath